McKesson (MCK)
(Delayed Data from NYSE)
$607.51 USD
+58.20 (10.60%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $604.00 -3.51 (-0.58%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$607.51 USD
+58.20 (10.60%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $604.00 -3.51 (-0.58%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
Zacks News
Medtronic (MDT) Gains Market Share Despite COVID Headwinds
by Zacks Equity Research
In Respiratory Interventions, despite the year-over-year headwind, as ventilator sales continue to return to pre-pandemic levels, Medtronic (MDT) gains about 400 basis points of share.
Are These Medical Stocks Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Quidel (QDEL) Rallies 17.4% Since Posting Q4 Earnings Beat
by Zacks Equity Research
Quidel (QDEL) stock rallies on better-than-expected fourth-quarter performance and strong diagnostics portfolio.
Here's Why You Should Invest in AmerisourceBergen (ABC) Stock
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment.
Insulet (PODD) Product Volume Up, COVID-Led Softness Persists
by Zacks Equity Research
Insulet's (PODD) drug delivery revenues surge led by increased production volumes, driven by higher-than-expected demand from its partner.
Henry Schein (HSIC) Expands Data Analytics to Private Practices
by Zacks Equity Research
Henry Schein's (HSIC) introduction of Jarvis Analytics for Private Practices offers practice owners a simple, powerful tool to help improve practice success through data-driven decisions.
McKesson (MCK) Up 5.1% Since Q3 Earnings: What's Driving It?
by Zacks Equity Research
Investors are optimistic about McKesson's (MCK) robust segmental performance and raised earnings outlook for fiscal 2022.
If You Invested $1000 in McKesson 10 Years Ago, This Is How Much You'd Have Now
by Zacks Equity Research
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
SmileDirectClub (SDC) Q4 Earnings Lag Estimates, Margin Falls
by Zacks Equity Research
SmileDirectClub (SDC) reports lower-than-expected results for the fourth quarter, issues full-year 2022 sales guidance.
Here's Why You Should Invest In Bruker (BRKR) Stock Now
by Zacks Equity Research
Investors are optimistic about Bruker's (BRKR) better-than-expected revenues and robust segmental performance.
Here's Why You Should Retain CVS Health (CVS) Stock for Now
by Zacks Equity Research
Investors are optimistic about CVS Health (CVS) on continued growth in its consumer-centric digital solutions.
National Vision (EYE) Q4 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Strength in America's Best and Eyeglass World brands drove National Vision's (EYE) performance in the fourth quarter of 2021.
McKesson (MCK) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
McKesson (MCK) could produce exceptional returns because of its solid growth attributes.
Here's Why You Should Invest In Henry Schein (HSIC) Now
by Zacks Equity Research
Investors are optimistic about Henry Schein's (HSIC) favorable dental business trends and bullish fourth-quarter 2021 performance.
Are These Medical Stocks a Great Value Stocks Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Chemed (CHE) Q4 Earnings Surpass Estimates, Revenues Miss
by Zacks Equity Research
Chemed (CHE) reports better-than-expected earnings for the fourth quarter, with a robust performance by the Roto-Rooter arm driving the top line.
Myriad Genetics (MYGN) Reports Loss in Q4, Gross Margin Improves
by Zacks Equity Research
Strength in Myriad Genetics' (MYGN) Molecular Diagnostic segment has drove Q4 sales despite a challenging business environment.
Teleflex (TFX) Q4 Earnings & Revenues Top Estimates, Margins Up
by Zacks Equity Research
Strong segmental performance in the domestic and international markets is driving Teleflex's (TFX) fourth-quarter top line.
Insulet (PODD) Q4 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Insulet's (PODD) fourth-quarter 2021 revenues improved year over year on a strong performance of Omnipod, both in U.S. and international markets.
NuVasive (NUVA) Q4 Earnings Miss Estimates, Gross Margin Up
by Zacks Equity Research
Continued strong international performance and introduction of products drove NuVasive's (NUVA) revenues in the fourth quarter of 2021.
Amedisys (AMED) Q4 Earnings Top Estimates, Margins Decline
by Zacks Equity Research
Robust performances by the Home Health and Hospice segments drove Amedisys' (AMED) fourth-quarter top line.
Exact Sciences (EXAS) Q4 Revenues Top Estimates, Margin Down
by Zacks Equity Research
Exact Sciences' (EXAS) legacy Screening business saw strong momentum on solid Cologuard volume growth during the fourth quarter.
Tandem Diabetes (TNDM) Q4 Earnings Lag Estimates, Revenues Top
by Zacks Equity Research
Robust domestic and international pump shipments are driving Tandem Diabetes' (TNDM) fourth-quarter top line.
Charles River (CRL) DSA Arm Sees Growth, Cell Supply Sluggish
by Zacks Equity Research
The acquisitions of Cognate BioServices and Vigene Biosciences contribute to the growth of Charles River's (CRL) Manufacturing Solutions arm.
Henry Schein (HSIC) Up 10.1% Since Posting Q4 Earnings Beat
by Zacks Equity Research
Henry Schein (HSIC) stock rallies on strong fourth-quarter performance and bullish 2022 EPS guidance.